3-[4-(1-formylpiperazin-4-yl)-benzylidenyl]-2-indolinone

Brands containing 3-[4-(1-formylpiperazin-4-yl)-benzylidenyl]-2-indolinone, food notes, and the most important drug interactions.

BRANDS

No registered brands found for this active ingredient.

FOOD NOTES

No food notes on record for this active ingredient.

MOST IMPORTANT INTERACTIONS

first 10 of 27

PropacetamolMODERATE
The serum concentration of Propacetamol can be increased when it is combined with 3-[4-(1-formylpiperazin-4-yl)-benzylidenyl]-2-indolinone.
Expert view
AcetaminophenMODERATE
The serum concentration of Acetaminophen can be increased when it is combined with 3-[4-(1-formylpiperazin-4-yl)-benzylidenyl]-2-indolinone.
Expert view
VoriconazoleMODERATE
The serum concentration of 3-[4-(1-formylpiperazin-4-yl)-benzylidenyl]-2-indolinone can be increased when it is combined with Voriconazole.
Expert view
3,5-diiodothyropropionic acidMINOR
The therapeutic efficacy of 3,5-diiodothyropropionic acid can be decreased when used in combination with 3-[4-(1-formylpiperazin-4-yl)-benzylidenyl]-2-indolinone.
Expert view
3,5-DiiodotyrosineMINOR
The therapeutic efficacy of 3,5-Diiodotyrosine can be decreased when used in combination with 3-[4-(1-formylpiperazin-4-yl)-benzylidenyl]-2-indolinone.
Expert view
BenzylthiouracilMINOR
The therapeutic efficacy of Benzylthiouracil can be decreased when used in combination with 3-[4-(1-formylpiperazin-4-yl)-benzylidenyl]-2-indolinone.
Expert view
DibromotyrosineMINOR
The therapeutic efficacy of Dibromotyrosine can be decreased when used in combination with 3-[4-(1-formylpiperazin-4-yl)-benzylidenyl]-2-indolinone.
Expert view
ElcatoninMINOR
The therapeutic efficacy of Elcatonin can be decreased when used in combination with 3-[4-(1-formylpiperazin-4-yl)-benzylidenyl]-2-indolinone.
Expert view
MethylthiouracilMINOR
The therapeutic efficacy of Methylthiouracil can be decreased when used in combination with 3-[4-(1-formylpiperazin-4-yl)-benzylidenyl]-2-indolinone.
Expert view
PalopegteriparatideMINOR
The therapeutic efficacy of Palopegteriparatide can be decreased when used in combination with 3-[4-(1-formylpiperazin-4-yl)-benzylidenyl]-2-indolinone.
Expert view